Bausch Health Companies Inc. (TSX:BHC)

Canada flag Canada · Delayed Price · Currency is CAD
9.04
-0.30 (-3.21%)
Oct 6, 2025, 4:00 PM EDT
-3.21%
Market Cap3.45B
Revenue (ttm)13.44B
Net Income (ttm)133.66M
Shares Outn/a
EPS (ttm)0.36
PE Ratio25.78
Forward PE1.68
Dividendn/a
Ex-Dividend Daten/a
Volume293,423
Average Volume383,369
Open9.35
Previous Close9.34
Day's Range9.03 - 9.35
52-Week Range5.91 - 13.74
Beta0.43
RSI43.66
Earnings DateOct 29, 2025

About Bausch Health Companies

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange Toronto Stock Exchange
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial numbers in USD Financial Statements

News

Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV

The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX™ offer energy-based treatment options that help maintain a youthful appea...

6 days ago - Accesswire

Bausch Health to Announce Third Quarter 2025 Results on October 29

LAVAL, QC / ACCESS Newswire / September 30, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2025 financial results after market close on Wednesday, October 29, 2025....

6 days ago - Accesswire

Bausch Health (BHC) Launches OraTalks Podcast to Address Dental Industry Issues

Bausch Health (BHC) Launches OraTalks Podcast to Address Dental Industry Issues

7 days ago - GuruFocus

Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry

Designed for dental professionals, OraTalks connects leading voices with insights to spark meaningful dialogue. Nine-episode inaugural season hosted by industry thought leader Melissa K.

7 days ago - Accesswire

BHC Makes Notable Cross Below Critical Moving Average

In trading on Thursday, shares of Bausch Health Companies Inc (Symbol: BHC) crossed below their 200 day moving average of $6.50, changing hands as low as $6.40 per share. Bausch Health Companies Inc s...

11 days ago - Nasdaq

Bausch + Lomb Breaks Below 200-Day Moving Average - Notable for BLCO

In trading on Thursday, shares of Bausch + Lomb Corporation (Symbol: BLCO) crossed below their 200 day moving average of $14.65, changing hands as low as $14.14 per share. Bausch + Lomb Corporation sh...

11 days ago - Nasdaq

Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan

Bausch Health (BHC) and Teva Accused of Antitrust Violations Over Xifaxan

13 days ago - GuruFocus

Bausch Health (BHC) Completes Acquisition of DURECT Corporation

Bausch Health (BHC) Completes Acquisition of DURECT Corporation

25 days ago - GuruFocus

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...

25 days ago - Accesswire

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAV...

25 days ago - PRNewsWire

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the Ameri...

25 days ago - Business Wire

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophth...

27 days ago - Business Wire

Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news

Bausch Health's Thermage Technology Reaches 5 Million Treatment Milestone | BHC stock news

4 weeks ago - GuruFocus

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin ...

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System | BHC Stock News

4 weeks ago - GuruFocus

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aest...

4 weeks ago - Accesswire

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...

5 weeks ago - Accesswire

Carl Icahn's Complete Divestment from Bausch Health Companies Inc

Carl Icahn's Complete Divestment from Bausch Health Companies Inc

6 weeks ago - GuruFocus

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...

6 weeks ago - Accesswire

A Look Into Bausch Health Companies Inc's Price Over Earnings

In the current session, the stock is trading at $7.81, after a 0.26% increase. Over the past month, Bausch Health Companies Inc. (NYSE: BHC) stock increased by 14.81% , and in the past year, by 32.32...

6 weeks ago - Benzinga

Bausch + Lomb board members resign after Icahn agreement ends

Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

7 weeks ago - Reuters

Alembic Pharma shares jump over 2% as USFDA approves Tretinoin Cream USP

Shares of Alembic Pharmaceuticals gained over 2% on Monday, August 19, after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...

7 weeks ago - Business Upturn

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...

7 weeks ago - Accesswire